GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ChromaDex Corp (NAS:CDXC) » Definitions » Cyclically Adjusted Price-to-FCF

ChromaDex (ChromaDex) Cyclically Adjusted Price-to-FCF : (As of Jun. 05, 2024)


View and export this data going back to 2008. Start your Free Trial

What is ChromaDex Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


ChromaDex Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for ChromaDex's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ChromaDex Cyclically Adjusted Price-to-FCF Chart

ChromaDex Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ChromaDex Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ChromaDex's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, ChromaDex's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ChromaDex's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ChromaDex's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where ChromaDex's Cyclically Adjusted Price-to-FCF falls into.



ChromaDex Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

ChromaDex's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, ChromaDex's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.003/131.7762*131.7762
=0.003

Current CPI (Mar. 2024) = 131.7762.

ChromaDex Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.017 100.560 -0.022
201409 -0.012 100.428 -0.016
201412 -0.010 99.070 -0.013
201503 -0.019 99.621 -0.025
201506 0.001 100.684 0.001
201509 -0.026 100.392 -0.034
201512 -0.032 99.792 -0.042
201603 -0.078 100.470 -0.102
201606 -0.013 101.688 -0.017
201609 -0.023 101.861 -0.030
201612 -0.010 101.863 -0.013
201703 -0.010 102.862 -0.013
201706 -0.134 103.349 -0.171
201709 -0.022 104.136 -0.028
201712 -0.079 104.011 -0.100
201803 -0.076 105.290 -0.095
201806 -0.140 106.317 -0.174
201809 -0.097 106.507 -0.120
201812 -0.095 105.998 -0.118
201903 -0.060 107.251 -0.074
201906 -0.164 108.070 -0.200
201909 -0.137 108.329 -0.167
201912 -0.015 108.420 -0.018
202003 -0.088 108.902 -0.106
202006 -0.027 108.767 -0.033
202009 -0.063 109.815 -0.076
202012 0.001 109.897 0.001
202103 -0.085 111.754 -0.100
202106 -0.120 114.631 -0.138
202109 -0.088 115.734 -0.100
202112 -0.072 117.630 -0.081
202203 -0.106 121.301 -0.115
202206 -0.057 125.017 -0.060
202209 -0.055 125.227 -0.058
202212 -0.007 125.222 -0.007
202303 0.036 127.348 0.037
202306 0.044 128.729 0.045
202309 0.005 129.860 0.005
202312 0.008 129.419 0.008
202403 0.003 131.776 0.003

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


ChromaDex  (NAS:CDXC) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


ChromaDex Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of ChromaDex's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


ChromaDex (ChromaDex) Business Description

Industry
Traded in Other Exchanges
Address
10900 Wilshire Boulevard, Suite 600, Los Angeles, CA, USA, 90024
ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segment namely Consumer Products, Ingredients segment and Analytical Reference Standards and Services. Majority of the revenue is earned from Consumer Products segment.
Executives
Brianna Gerber officer: SVP Finance / Interim CFO C/O CHROMADEX, INC., 1735 FLIGHT WAY, SUITE 200, TUSTIN CA 92782
Champion River Ventures Ltd 10 percent owner C/O 7F, CHEUNG KONG CENTER, 2 QUEEN'S ROAD, CENTRAL K3 00000
Jaksch Frank L Jr director, 10 percent owner, officer: Chief Executive Officer 10005 MUIRLANDS BOULEVARD, SUITE G FIRST FLOOR, IRVINE CA 92618
Robert N Fried director 100 NORTH CRESCENT DRIVE, BEVERLY HILLS CA 90210
Steven D Rubin director OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Li Ka Shing 10 percent owner 79 DEEP WATER BAY ROAD, HONG KONG F4 00000
Chau Hoi Shuen Solina Holly 10 percent owner SUITES PT. 2909 & 2910, HARBOUR CENTRE, 25 HARBOUR ROAD, WANCHAI K3 999077
Hamed Shahbazi director C/O CHROMADEX, INC., 1735 FLIGHT WAY, SUITE 200, TUSTIN CA 92782
Ann Cohen director C/O CHROMADEX CORPORATION, 10900 WILSHIRE BLVD. STE 600, LOS ANGELES CA 90024
Kristin Patrick director 3329 CAY DRIVE, SHERMAN OAKS CA 91423
Ng Wang Yu Gary director ROOM 1709 HARBOUR CENTER, 25 HARBOUR ROAD, WANCHAI K3 -
Caroline S Levy director 2424 N FEDERAL HIGHWAY, SUITE 208, BOCA RATON FL 33431
Stephen A Block director INTERNATIONAL FLAVORS & FRAGRANCES INC., 521 WEST 57TH ST, NEW YORK NY 10019
Lisa Hatton Harrington officer: General Counsel 53 SEA TERRACE, NEWPORT COAST CA 92657
Kevin M Farr officer: Chief Financial Officer MATTEL, INC., 333 CONTINENTAL BLVD, M1-1518, EL SEGUNDO CA 90245

ChromaDex (ChromaDex) Headlines

From GuruFocus

ChromaDex Named Brianna Gerber Chief Financial Officer

By Business Wire Business Wire 01-05-2023